Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

BTIG raised the firm’s price target on Verona Pharma (VRNA) to $77 from $51 and keeps a Buy rating on the shares. The company’s Q4 ...

Wells Fargo analyst Tiago Fauth raised the firm’s price target on Verona Pharma (VRNA) to $74 from $64 and keeps an Overweight rating on the ...

Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...

Verona Pharma plc (NASDAQ:VRNA – Get Free Report)’s share price dropped 2.5% during mid-day trading on Tuesday . The company traded as low as $45.64 and last traded at $45.83. Approximately 105,374 ...

Sanctuary Advisors LLC acquired a new stake in shares of Verona Pharma plc (NASDAQ:VRNA – Free Report) in the third quarter, ...

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investing.com - Investors should expect some moderation in growth in the S&P 500 in 2025 after two years of over 20% expansion in the benchmark index, according to ...